metformin has been researched along with Candidiasis, Vulvovaginal in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Candidiasis, Vulvovaginal: Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nauck, M | 1 |
| del Prato, S | 1 |
| Meier, JJ | 1 |
| Durán-García, S | 1 |
| Rohwedder, K | 1 |
| Elze, M | 1 |
| Parikh, SJ | 1 |
| Roeleveld-Versteegh, AB | 1 |
| Jansen, M | 1 |
| De Vroede, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonyl[NCT00660907] | Phase 3 | 1,217 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment. (NCT00660907)
Timeframe: Baseline to Week 52
| Intervention | kg (Least Squares Mean) |
|---|---|
| Dapagliflozin Plus Metformin | -3.22 |
| Glipizide Plus Metformin | 1.44 |
To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone. (NCT00660907)
Timeframe: Baseline to Week 52
| Intervention | percent (Least Squares Mean) |
|---|---|
| Dapagliflozin Plus Metformin | -0.52 |
| Glipizide Plus Metformin | -0.52 |
To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value. (NCT00660907)
Timeframe: Baseline to Week 52
| Intervention | Percentage of participants (Least Squares Mean) |
|---|---|
| Dapagliflozin Plus Metformin | 3.5 |
| Glipizide Plus Metformin | 40.8 |
To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value. (NCT00660907)
Timeframe: Baseline to Week 52
| Intervention | Percentage of participants (Least Squares Mean) |
|---|---|
| Dapagliflozin Plus Metformin | 33.3 |
| Glipizide Plus Metformin | 2.5 |
1 trial available for metformin and Candidiasis, Vulvovaginal
| Article | Year |
|---|---|
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabet | 2013 |
1 other study available for metformin and Candidiasis, Vulvovaginal
| Article | Year |
|---|---|
[A twelve-year old girl with diabetes mellitus type 2].
Topics: Acanthosis Nigricans; Candidiasis, Vulvovaginal; Child; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1998 |